ORION Biotech Catalyst Calendar
Menu
Skip to company dates

TG Therapeutics (TGTX) pipeline and stated timing

Name in SEC filings: TG THERAPEUTICS, INC.

Pipeline at a glance

ProgramEventStageStated timingFiling
ublituximab submission—second half of 20268-K ·
ublituximab subcutaneous/data readoutPhase 3year-end 2026 or early 20278-K ·

Source: ORION, orionbiotechai.com/company/TGTX, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/TGTX

Nearest upcoming stated timing: ublituximab · NDA/BLA submission · second half of 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
ublituximab subcutaneousClinical resultsyear-end 2026 or early 2027
“Top-line Phase 3 data is expected year-end 2026 or early 2027”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

ublituximab subcutaneousClinical resultsyear-end 2026 or early 2027
“Top-line Phase 3 data expected year-end 2026 or early 2027”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

ublituximabSubmissionsecond half of 2026
“with the goal of submitting a supplemental BLA in the second half of 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked .

No historical announcement trail is retained for this company in this catalog.

Selected registry record

Ublituximab · NCT04130997

Condition in the selected registry record
Relapsing Multiple Sclerosis (RMS)
Phase in the selected registry record
Phase 3
Identity checked

Original ClinicalTrials.gov record · Open the selected study

Retained company–study identity sources

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch TGTX

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for TGTX. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See TGTX in the calendar · Review labels and methodology

A New Drug Application (NDA) or Biologics License Application (BLA) asks the FDA to approve a drug or biologic for sale.Topline results are the main summary results of a clinical trial, released before the full data.